Aclarion Expands Nociscan Use at Weill Cornell in Spine Trial with Dr. Roger Härtl

Aclarion, Inc. (Nasdaq: ACON, ACONW) announced a second commercial agreement with Weill Cornell Medicine to expand the use of its Nociscan platform in a clinical trial led by renowned neurosurgeon Roger Härtl, MD. The trial, titled “Bone Marrow Aspirate Concentrate Injection with MRI’s – a Prospective Randomized Controlled Trial” (IRB Protocol No. 24-09027977), will evaluate the long-term effects of lumbar microdiscectomy surgery with and without intradiscal bone marrow aspirate concentrate (BMAC) injection on patient outcomes and intervertebral disc health over two years.

The study aims to deepen understanding of degenerative disc disease (DDD), its causes, and potential treatments. Dr. Härtl, founder and director of the Weill Cornell Medicine Center for Comprehensive Spine Care and co-director of Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center, noted: “Our scientific interest focuses on clinical and basic science research surrounding innovative and less invasive surgical and biological treatment strategies for degenerative diseases of the spine. This trial strives to enhance our understanding of disc degeneration in patients, and illuminate chemical aspects of disc degeneration not available with traditional imaging.”

This is the second trial at Weill Cornell to incorporate Nociscan, Aclarion’s evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan uses magnetic resonance spectroscopy (MRS) data and proprietary augmented intelligence algorithms to quantify chemical biomarkers associated with disc pain, providing critical insights that can improve treatment success rates. According to Aclarion, when all Nociscan-identified pain positive discs are treated, surgical success rates reach 97%.

Ryan Bond, Chief Strategy Officer of Aclarion, commented: “We are pleased to engage in this trial with Dr. Härtl and his team at Weill Cornell. Not only are Dr. Härtl and his colleagues renowned for their clinical excellence, their commitment to pioneering research is evident through this prospective randomized trial evaluating disc degeneration and the potential effects of bone marrow aspirate concentrate. Progressive trials such as this one are a clear example for how healthcare advances – investigating a major global health issue, like degenerative disc disease, while using innovative tools like Nociscan.”

Chronic low back pain (cLBP) affects approximately 266 million people worldwide, according to a study in Global Spine Journal (Ravindra VM, 2018). Aclarion’s Nociscan platform addresses this significant healthcare burden by providing objective biomarker data to guide treatment decisions. For more information, visit Aclarion’s latest news or the Nociscan center map. The company’s newsroom is also available at https://tinyurl.com/aconnewsroom.